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Background: Controversy exists whether young patients diagnosed with colorectal cancer have a poorer
prognosis. Although younger patients are more likely to have certain poor prognostic factors, prior studies have
shown mixed results in terms of overall prognosis, which may be due to lack of adjustment for confounding
factors. The primary objective of our study was to determine the effect of age on survival following treatment of
colorectal cancer in the Province of Manitoba, Canada, while controlling for important cofactors.
Methods: This was a population-based analysis of all adult patients (age ≥18 years) diagnosed with adenocarcinoma
of the colon or rectum between 1 January 2004 and 31 December 2006 in the Province of Manitoba. Patient, tumor,
and treatment factors were identified using administrative data. Five-year Kaplan-Meier survival and Cox proportional
hazards model were analyzed to determine whether young age (45 years of age or younger) was associated with a
poorer prognosis, while controlling for confounding variables.
Results: Of the 2,086 patients identified, 70 (3.36%) were considered young. These patients were more likely to
have T4 tumors and node-positive disease. Older patients had more advanced comorbidities. Young age was an
independent predictor of better survival. Poorer survival was associated with male gender, increasing stage, higher
grade, comorbidity, lower socioeconomic status, and lack of receipt of surgery or chemotherapy.
Conclusions: Young people make up a small minority of patients with colorectal cancer. Young patients present
with more locally advanced colorectal cancer. Despite this, on a population basis, their prognosis may be more
favorable than their older counterparts when controlling for disease, patient, and treatment factors.Background
Colorectal cancer (CRC) is the most common malig-
nancy of the gastrointestinal tract, the third most com-
mon cancer overall in Canada [1], and the second
leading cause of cancer-related death. Colorectal cancer
is typically a disease of the elderly, with over 90% of
cases in patients >55 years of age [2]. The vast majority
of cases in young patients (<40 years of age) are
sporadic, as only 16% of young patients have been
reported to have a predisposing factor and 23% to have a
positive family history [3].* Correspondence: amckay3@exchange.hsc.mb.ca
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unless otherwise stated.Whether young patients with CRC have a different
biological behavior and carry a poorer prognosis remains
controversial. Although younger patients are more likely
to have mucinous or poorly differentiated tumors, in-
cluding signet ring tumors [3,4], studies have shown
mixed results in terms of prognosis. Some studies sug-
gested that younger age was a poor prognostic factor
[5-7]. Other studies have suggested that this is not the
case and young patients do at least as well, and possibly
better, than their older counterparts [8-12]. The contra-
dictory results of the prior studies may be due to inclu-
sion of study subjects from single referral centers and/or
lack of adjustment for potential confounding factors.
The objective of the current study was to determine
the effect of age at diagnosis on the survival following
treatment of CRC in the Province of Manitoba, Canada,
while controlling for disease factors and treatmentLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,








n = 70 n = 1459 n = 557 P value
Diagnosis year (n (%)) 0.1349
2004 28 (40.00) 502 (34.41) 176 (31.60)
2005 26 (37.14) 451 (30.91) 194 (34.83)
2006 16 (22.86) 506 (34.68) 187 (33.57)
Age (mean ± SD (range)) 38 ± 4.82 (20-44) 66 ± 9.21 (45-79) 85 ± 4.08 (80-103)
Age (median (interquartile range) 39 (36-41) 67 (59-74) 84 (82-87) <0.0001
Gender (n (%)) <0.0001
Female 35 (50.00) 607 (41.60) 321 (57.63)
Male 35 (50.00) 852 (58.40) 236 (42.37)
Site (n (%)) <0.0001
Colon 51 (72.86) 912 (62.51) 413 (74.15)
Rectosigmoid 2 (2.86) 144 (9.87) 56 (10.05)
Rectum 17 (24.29) 403 (27.62) 88 (15.80)
AJCC stage (n (%)) <0.0001
I 9 (12.86) 296 (20.29) 98 (17.59)
II 25 (35.71) 369 (25.29) 181 (32.50)
III 22 (31.43) 449 (30.77) 139 (24.96)
IV 13 (18.57) 319 (21.86) 107 (19.21)
Unknown/NA 1 (1.43) 26 (1.78) 32 (5.75)
T stage (n (%)) 0.0267
NA 1 (0.07)
T0 1 (0.07) 2 (0.36)
T1 9 (12.86) 182 (12.47) 72 (12.93)
T2 6 (8.57) 191 (13.09) 55 (9.87)
T3 33 (47.14) 771 (52.84) 284 (50.99)
T4 20 (28.57) 234 (16.04) 84 (15.08)
TX 2 (2.86) 79 (5.41) 58 (10.41)
Tis 2 (0.36)
Nodes (n (%)) 0.0058
N0 37 (52.86) 806 (55.24) 345 (61.94)
N1 19 (27.14) 397 (27.21) 123 (22.08)
N2 13 (18.57) 232 (15.90) 60 (10.77)
NA 1 (0.07)
NX 1 (1.43) 23 (1.58) 29 (5.21)
Metastasis (n (%)) 0.1626
M0 56 (80.00) 1124 (77.04) 436 (78.28)
M1 13 (18.57) 319 (21.86) 107 (19.21)
MX 1 (1.43) 15 (1.03) 14 (2.51)
NA 1 (0.07)
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Table 1 Patient demographics (Continued)
Grade/differential (n (%)) 0.0038
1 - well differentiated 2 (2.86) 87 (5.96) 35 (6.28)
2 - moderately differentiated 45 (64.29) 1003 (68.75) 329 (59.07)
3 - poorly differentiated 8 (11.43) 180 (12.34) 75 (13.46)
4 - undifferentiated 4 (0.27) 4 (0.72)
9 - not determined/not available 15 (21.43) 185 (12.68) 114 (20.47)
Residence at diagnosis (n (%)) 0.0275
Rural 23 (32.86) 572 (39.20) 184 (33.03)
Urban 47 (67.14) 887 (60.80) 373 (66.97)
Distance from CancerCare (n (%)) 0.0300
<21 km 44 (62.86) 835 (57.23) 341 (61.22)
21-100 km 11 (15.71) 254 (17.41) 71 (12.75)
101-500 km 14 (20.00) 324 (22.21) 138 (24.78)
501+ km 1 (1.43) 46 (3.15) 7 (1.26)
Charlson score (CCI) (n (%)) <0.0001
CCI count =0 39 (55.71) 604 (41.40) 194 (34.83)
CCI count =1 29 (41.43) 558 (38.25) 178 (31.96)
CCI count >1 2 (2.86) 297 (20.36) 185 (33.21)
Socioeconomic status (n (%)) <0.0001
1 27 (38.57) 275 (18.85) 160 (28.73)
2 11 (15.71) 318 (21.80) 125 (22.44)
3 9 (12.86) 323 (22.14) 105 (18.85)
4 10 (14.29) 289 (19.81) 75 (13.46)
5 13 (18.57) 246 (16.86) 76 (13.64)
NA 8 (0.55) 16 (2.87)
AJCC (American Joint Committee on Cancer); CCI (Charlson Comorbidity Index); MX (M status cannot be assessed); NA (Not Available); Tis (Carcinoma in situ); Tx
(T status cannot be assessed).
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ing some of the biases of single center studies.
Methods
This study was approved by the University of Manitoba
Health Research Ethics Board. It was a population-based
historical cohort analysis of all adult patients (age ≥18 years)
diagnosed with adenocarcinoma of the colon or rectum
between 1 January 2004 and 31 December 2006 in the
Province of Manitoba. Patients were identified using the
Manitoba Cancer Registry (MCR), which contains informa-
tion regarding all Manitobans diagnosed with a malignancy
as mandated by Manitoba law [13]. The MCR was used to
identify patients based on International Classification of
Diseases-10 coding. Patients who were diagnosed with
CRC at the same date as death, through autopsy or radio-
graphic findings, were excluded (n = 3). From this registry,
detailed demographic data including the age, gender, and
postal code of the subjects’ home addresses was obtained.
Socioeconomic status (income quintile) was assigned based
on the mean household income in the neighborhood ofresidence, as determined from the 2006 Canadian Census
data. The MCR also provided detailed tumor-specific infor-
mation, including the histologic diagnosis and the TNM
status at the time of diagnosis, and subsequent treatment
information for each patient. This included dates of treat-
ment, the specific surgical procedures performed, and re-
ceipt of chemotherapy or radiation therapy.
Information retrieved through this database was linked
to other administrative databases maintained by Manitoba
Health, the agency responsible for providing health insur-
ance to virtually all citizens of the Province. The linkages
were made using each patient’s Personal Health Identifica-
tion Number, which was scrambled to maintain patient
confidentiality. The Medical Claims (Physician Billing)
Database contains patient-specific information about con-
tacts with the healthcare system. This provided informa-
tion about consultations and services provided to patients
both in and out of hospital. These records identified the
patient, the healthcare provider, and the location, type,
and date of services rendered. In addition, the Hospital
Separations Abstracts provided admission dates, discharge






n = 70 n = 1459 n = 557 P value
Surgery type (n (%)) 0.0001
Local resection 3 (4.29) 40 (2.74) 15 (2.69)
Major surgery 55 (78.57) 1166 (79.92) 407 (73.07)
None 10 (14.29) 196 (13.43) 124 (22.26)




Adjuvant 34 (48.57) 509 (34.89) 35 (6.28)
Local procedure 3 (4.29) 19 (1.30) 1 (0.18)
Neoadjuvant 2 (2.86) 49 (3.36) 2 (0.36)
None 24 (34.29) 804 (55.11) 512 (91.92)




Adjuvant 6 (8.57) 159 (10.90) 16 (2.87)
Local procedure 1 (1.43) 14 (0.96) 1 (0.18)
Neoadjuvant 1 (1.43) 57 (3.91) 3 (0.54)
None 61 (87.14) 1196 (81.97) 529 (94.97)
Palliative 1 (1.43) 33 (2.26) 8 (1.44)
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including complications of treatment. From these data, pa-
tient comorbidity was calculated according to a modifica-
tion of the Charlson score [14-16] to allow this to be
controlled in the analyses. The Manitoba Health Registry
contains information on every Manitoban covered by the
Manitoba healthcare insurance plan and provides up-to-
date vital statistics information for each patient.
Young age was defined as being less than 45 years of
age, and elderly patients were defined as being 80 years
of age and above. Five-year overall survival was deter-
mined from the date of diagnosis. The survival analysis
included a follow-up period lasting 5 years after the date of
diagnosis or until 30 June 2011 (for those patients without
5 years follow-up). Because geography may influence treat-
ment when patients must travel large distances to receive
highly specialized care [17], the distance needed to travel to
CancerCare Manitoba (the single tertiary care center in the
province with most of the medical oncologists and all of
the radiation oncologists in the province in the study time
period) was included in the analysis. Patients were put into
groups based on the distance required for travel (<21 km,
21 to 100 km, 101 to 500 km, and 501+ km). Geographical
distance to CancerCare Manitoba was determined using
SAS statistical software (SAS Institute Inc., Cary, NC, USA)
and the Statistics Canada Postal Code Conversion File
(PCCF+ Version 5G; Statisitcs Canada, Health Analysis
Division. Ottawa, Ontario, K1A 0T6).
Standard descriptive analysis and treatment frequency
are reported. Kaplan-Meier 5-year survival and a Cox
proportional hazards model were performed. Two-sided
P values were reported with significance set at P = 0.05.
SAS statistical software versions 9.1 and 9.2 (SAS Insti-
tute Inc.) were utilized for statistical analyses.
Results
Between 1 January 2004 and 31 December 2006 a cohort
of 2,086 patients were diagnosed with colorectal adeno-
carcinomas in the Province of Manitoba. The median
age of the entire cohort was 72 years, with range of 20
to 103 years. There was a slight male predominance of
53.8%. Seventy patients (3.36%) were considered young
(45 years of age or younger). The patient demographics
are listed in Table 1. Young patients were more likely to
have T4 tumors and node-positive disease. Older pa-
tients had more advanced comorbidities.
The treatments received by patients are listed accord-
ing to age in Table 2 and according to stage in Table 3.
Patients younger than 45 years were significantly more
likely to receive chemotherapy, whereas elderly patients
(≥80 years) were significantly less likely to receive sur-
gery, chemotherapy, or radiation.
Figure 1 demonstrates the overall 5-year survival for
the entire cohort according to age. The overall 5-yearsurvival for patients under 45 years, patients aged 45
to 80 years, and patients 80 years and older were 67.1%,
54.7%, and 33.4%, respectively. Advanced age was associated
with decreased overall survival. In this analysis, younger
patients were found to have a superior overall survival
relative to their older counterparts. The predictive factors
for overall survival on univariate analysis are shown in
Table 4 and the multivariate analysis is shown in Table 5.
Young age remained a significant independent predictor
of better survival while controlling for tumor factors,
patient factors, and treatment factors. Poorer survival was
associated with male gender, increasing stage, higher grade,
increased comorbidity, lower socioeconomic status, and
lack of receipt of surgery or chemotherapy.
Discussion
While the incidence of CRC cases in older adults has
remained stable, the incidence in young adults (aged 20 to
40 years) has been steadily increasing [18]. From 1973 to
1999, the Surveillance, Epidemiology, and End Results
registry indicated that colon and rectal cancers increased
by 17% and 75%, respectively, in persons aged 20 to
40 years, whereas the rates in those 50 years and older
remained stable or declined. CRC is one of the top ten
most common cancers amongst those aged 20 to 49 years,
Figure 1 Overall survival according to age.
Table 3 Treatments received according to stage
Stage
I II III IV Unknown/NA
n = 403 n = 575 n = 610 n = 439 n = 59 P value
Age group (n (%)) <0.0001
45-79 296 (73.45) 369 (64.17) 449 (73.61) 319 (72.67) 26 (44.07)
80+ 98 (24.32) 181 (31.48) 139 (22.79) 107 (24.37) 32 (54.24)
<45 9 (2.23) 25 (4.35) 22 (3.61) 13 (2.96) 1 (1.69)
Surgery type (n (%)) <0.0001
Local resection 29 (7.20) 12 (2.09) 10 (1.64) 6 (1.37) 1 (1.69)
Major surgery 290 (71.96) 527 (91.65) 575 (94.26) 225 (51.25) 11 (18.64)
None 30 (7.44) 33 (5.74) 19 (3.11) 204 (46.47) 44 (74.58)
Polypectomy 54 (13.40) 3 (0.52) 6 (0.98) 4 (0.91) 3 (5.08)
Chemo type (n (%)) <0.0001
Adjuvant 7 (1.74) 127 (22.09) 307 (50.33) 135 (30.75) 2 (3.39)
Local procedure 1 (0.25) 6 (1.04) 11 (1.80) 5 (1.14)
Neoadjuvant 2 (0.50) 17 (2.96) 26 (4.26) 8 (1.82)
None 393 (97.52) 416 (72.35) 255 (41.80) 219 (49.89) 57 (96.61)
Palliative 9 (1.57) 11 (1.80) 72 (16.40)
Radiation therapy type (n (%)) <0.0001
Adjuvant 5 (1.24) 49 (8.52) 111 (18.20) 16 (3.64)
Local procedure 3 (0.74) 4 (0.70) 8 (1.31) 1 (0.23)
Neoadjuvant 2 (0.50) 19 (3.30) 35 (5.74) 5 (1.14)
None 392 (97.27) 493 (85.74) 451 (73.93) 394 (89.75) 56 (94.92)
Palliative 1 (0.25) 10 (1.74) 5 (0.82) 23 (5.24) 3 (5.08)
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Table 4 Predictors of 5-year survival on univariate analysis
Event (n (%)) Hazard ratio 95% CI P value
Diagnosis age group <0.0001
45-79 661 (45.31) 1.54 1.02-2.34
80+ 371 (66.61) 2.87 1.89-4.38
<45 23 (32.86) 1 Ref
Gender 0.4521
Female 478 (49.64) 1 Ref
Male 577 (51.38) 1.05 0.93-1.18
Site 0.0069
Colon 719 (52.25) 1 Ref
Rectosigmoid 103 (50.99) 0.93 0.75-1.14
Rectum 233 (45.87) 0.79 0.68-0.91
Collaborative stage <0.0001
I 116 (28.78) 1 Ref
II 194 (33.74) 1.21 0.96-1.53
III 284 (46.56) 1.87 1.50-2.32
IV 413 (94.08) 8.46 6.85-10.44
Unknown/NA 48 (81.36) 6.7 4.78-9.39
Income quintile <0.0001
1 276 (59.74) 1 Ref
2 244 (53.74) 0.88 0.74-1.05
3 209 (47.83) 0.73 0.61-0.88
4 165 (44.12) 0.66 0.54-0.80
5 139 (41.49) 0.61 0.50-0.75
NF 22 (91.67) 2.75 1.78-4.24
Grade/differentiated <0.0001
1 - well differentiated 43 (34.68) 1 Ref
2 - moderately differentiated 624 (45.32) 1.39 1.02-1.89
3 - poorly differentiated 152 (57.79) 2.18 1.56-3.06
4 - undifferentiated 5 (62.50) 3 1.19-7.57
9 - not determined/not available 231 (73.57) 3.65 2.64-5.06
Comorbidity <0.0001
CCI count <1 239 (28.55) 1 Ref
CCI count =1 454 (59.35) 2.74 2.34-3.20
CCI count >1 362 (74.79) 4.28 3.63-5.04
Residence 0.4599
Rural 404 (51.86) 1 Ref
Urban 651 (49.81) 0.95 0.84-1.08
Distance from CancerCare 0.348
<21 km 599 (49.10) 1 Ref
21-100 km 170 (50.60) 1.02 0.86-1.20
101-500 km 257 (53.99) 1.12 0.97-1.29
501+ km 29 (53.70) 1.25 0.86-1.81
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Table 4 Predictors of 5-year survival on univariate analysis (Continued)
Surgery type <0.0001
Major surgery 707 (43.43) 0.17 0.15-0.19
Local resection 15 (25.86) 0.09 0.05-0.15
Polypectomy 27 (38.57) 0.14 0.10-0.21
None 306 (92.73) 1 Ref
Chemotherapy type <0.0001
None 690 (51.49) 1 Ref
Neoadjuvant 19 (35.85) 0.54 0.34-0.85
Adjuvant 254 (43.94) 0.71 0.62-0.82
Palliative 83 (90.22) 2.53 2.01-3.18
Adjuvant with local procedure 9 (39.13) 0.61 0.32-1.18
Radiation therapy type <0.0001
None 929 (52.02) 1 Ref
Neoadjuvant 18 (29.51) 0.45 0.28-0.71
Adjuvant 65 (35.91) 0.56 0.43-0.71
Palliative 39 (92.86) 2.67 1.94-3.69
Adjuvant with local procedure 4 (25.00) 0.38 0.14-1.00
CCI (Charlson Comorbidity Index); NA (Not Available); NF (Not Formatted).
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one of the top four most common cancers [19].
Despite having many poor prognostic factors, young
patients in this population-based study had better 5-year
overall survival both in the univariate (unadjusted) and
multivariate analysis. This study provides contemporary
data for discussion for newly diagnosed young patients
with CRC and their healthcare providers.
In this study, younger patients were found to have
more locally advanced tumors at the time of diagnosis.
They had a greater proportion of T4 tumors as well as
node-positive tumors. Others have found similar find-
ings with younger patients having higher stage disease
[4,20,21] and less favorable histologic subtypes than
older patients [21-23]. It is not clear why younger pa-
tients tend to present with more advanced disease.
Perhaps, because of their young age, physicians are less
likely to suspect malignant disease than they are older
patients, thus leading to a delay in appropriate investi-
gations and diagnosis. Another potential explanation is
that younger patients would generally not be included
in CRC screening initiatives and would be less likely
to have early cancers diagnosed through these screening
initiatives. It was not possible to determine whether
cancers were detected through screening from the
available databases.
Despite these poor prognostic factors, the outlook in
this group of patients is actually more favorable. When
controlling for tumor, patient, and treatment factors,
young patients had a superior 5-year overall survival. This
is in contrast to some older studies that suggested youngpatients had a worse prognosis [5,7,8]. Other more recent
studies have suggested that the survival is no different
when adjusting for confounding variables [9-12].
In this study, young age was defined as 45 years and
under. CancerCare Ontario and the Candian Cancer So-
ciety have previously used this definition [24]. The pro-
portion of young patients was small at 3.36%, in keeping
with other studies [4,15,25]. Expanding the definition of
young age to include patients who were 50 years and
under would have captured as many as 13% of patients
[25]. This would improve the statistical power of the
analysis, but potentially lower the clinical relevance of
the possible influence of a different biological behavior
among colon cancers in younger patients; this would
have been diluted by including many slightly older
patients carrying cancers with a more typical biology.
In this study, tumor stage and treatment variables
were controlled for; despite this, however, it is likely that
younger patients were treated more aggressively. This
may partly explain their improved prognosis. This ana-
lysis was able to adjust for the receipt of chemotherapy
(or not), but it was unable to control for differences in
chemotherapuetic agents and duration of treatment/dis-
continuation of treatment. With recent advances in
chemotherapy for CRC, it is possible that younger pa-
tients were treated with more aggressive, but potentially
more toxic, regimens compared to older patients. It is
also possible that older patients were more likely to dis-
continue chemotherapy early due to side effects or other
reasons. The databases used in this study do not collect
information regarding performance status, which would
Table 5 Multivariate Cox proportional hazards model of 5-year overall survival
Event (n(%)) Adjusted hazard ratio 95% CI P value
Diagnosis age group <0.0001
45-79 661 (45.31) 1.29 0.85-1.97
80+ 371 (66.61) 1.95 1.27-3.01
<45 23 (32.86) 1 Ref
Gender 0.0045
Female 478 (49.64) 1 Ref
Male 577 (51.38) 1.2 1.06-1.36
Collaborative stage <0.0001
I 116 (28.78) 1 Ref
II 194 (33.74) 1.22 0.96-1.56
III 284 (46.56) 1.72 1.34-2.20
IV 413 (94.08) 6.12 4.73-7.91
Unknown/NA 48 (81.36) 2.48 1.71-3.59
Income quintile 0.0003
1 276 (59.74) 1 Ref
2 244 (53.74) 1.09 0.91-1.30
3 209 (47.83) 0.95 0.79-1.14
4 165 (44.12) 0.91 0.75-1.11
5 139 (41.49) 0.74 0.60-0.91
NF 22 (91.67) 1.89 1.21-2.95
Grade/differentiated 0.0004
1 - well differentiated 43 (34.68) 1 Ref
2 - moderately differentiated 624 (45.32) 1.15 0.84-1.58
3 - poorly differentiated 152 (57.79) 1.59 1.13-2.25
4 - undifferentiated 5 (62.50) 1.93 0.76-4.92
9 - not determined/not available 231 (73.57) 1.52 1.08-2.14
Comorbidity <0.0001
CCI count <1 239 (28.55) 1 Ref
CCI count =1 454 (59.35) 2.06 1.72-2.47
CCI count >1 362 (74.79) 2.9 2.41-3.49
Surgery type <0.0001
Major surgery 707 (43.43) 0.32 0.26-0.40
Local resection 15 (25.86) 0.18 0.09-0.35
Polypectomy 27 (38.57) 0.51 0.33-0.80
None 306 (92.73) 1 Ref
Chemotherapy type <0.0001
None 690 (51.49) 1 Ref
Neoadjuvant 19 (35.85) 0.76 0.48-1.22
Adjuvant 254 (43.94) 0.6 0.50-0.72
Palliative 83 (90.22) 0.4 0.30-0.52
Adjuvant with local procedure 9 (39.13) 1.08 0.47-2.51
CCI (Charlson Comorbidity Index); NA (Not Available); NF (Not Formatted).
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patients for more aggressive systemic treatment.
Another possible explanation for the improved prog-
nosis is that this analysis used overall survival as the pri-
mary outcome measure, rather than cancer-specific
survival. It was felt that this a more robust outcome
measure that would be less sensitive to biases in deter-
mining cause of death. Since younger patients are ex-
pected to have fewer comorbidities and fewer competing
causes of death, this could also contribute to their more
favorable 5-year overall survival. Although the multi-
variate analysis did adjust for the burden of comorbid
disease, this adjustment may not have been complete.
A limitation of the study is that younger patients may
have had a higher proportion of hereditary CRC syn-
dromes than older patients. This could not be evaluated
with the available data. Furthermore, important pathologic
features such as microsatellite instability or results or im-
munohistochemistry for DNA mismatch repair abnormal-
ities are not captured in the MCR. Although studies
suggest that only a small minority of young patients with
CRC have genetic or other predisposing factors [3,21], it is
likely that a higher proportion of patients with factors
such as hereditary nonpolyposis CRC existed in the youn-
ger cohort. Since hereditary nonpolyposis CRC tumors are
associated with a better prognosis [26-28], this could par-
tially be responsible for this study’s findings.
The biggest strength of this paper is that it is a population-
based analysis, and examines all patients whether they had
surgical resection or not. Thus, it avoids some of the
biases associated with series of selected patients from
single institution referral centers.
Conclusions
Young people make up a small minority of patients with
CRC. Young patients present with more locally advanced
disease at diagnosis. Their prognosis is more favorable
than their older counterparts when controlling for dis-
ease, patient, and treatment factors.
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